Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation clinical trial (NCT06465953). Contact the study team or your healthcare provider for specific answers.

Question 2

How does ivosidenib compare to azacitidine in terms of side effects and effectiveness?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation clinical trial (NCT06465953). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential risks and benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation clinical trial (NCT06465953). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits, and what will those visits involve?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation clinical trial (NCT06465953). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation clinical trial (NCT06465953). Contact the study team or your healthcare provider for specific answers.

What this study is about